EASE研究PPT课件.ppt

《EASE研究PPT课件.ppt》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、EzetimibeAdd-ontoStatinTherapyforEffectivenessTrialPresentedatAmericanCollegeofCardiologyScientificSessions2004PresentedbyDr.ThomasPearsonEASETrialEndpoints(6weeks):PercentchangefrombaselineinLDLcholesterolintheoverallpopulationandbyNCEPATPIIICHDriskcategoryEASETrialPresentedatACCScientifi

2、cSessions20043,030Patientswithlow-densitylipoprotein(LDL)cholesterolexceedingNationalCholesterolEducationProgram(NCEP)AdultTreatmentPanel(ATP)IIIgoals.Randomized,double-blind,multicenterEzetimiben=2,020Placebon=1,010TreatmentAddedtoadoseofanystatin(40%atorvastatin,29%simvastatin,22%pravast

3、atin,10%other)ReductioninTriglyceridesp<0.001PresentedatACCScientificSessions2004EASETrialAlargeproportionofpatientsinthetrialhaddiabetes(38.4%)andmetabolicsyndromebyNCEPATPIIIcriteria(60%).BaselineLDLlevelswere129mg/dlintheoverallpopulation,123mg/dlinthecoronaryheartdisease(CHD)orCHDriske

4、quivalentgroup,147mg/dlinthemultipleriskfactorsgroup,and167mg/dlinthe<2riskfactorsgroup.Theezetimibearmhadalargerreductionintriglyceridesandalargerincreaseinhigh-densitylipoprotein(HDL)levels.EzetimibePlacebomg/dlIncreaseinHigh-DensityLipoprotein(HDL)p<0.001EzetimibePlaceboReductioninLDLp<

5、0.001PresentedatACCScientificSessions2004EASETrialIntheoverallstudypopulation,alargerpercentchangefrombaselineinLDLlevelsoccurredintheezetimibearmversusplacebo.Thefollow-upLDLlevelintheezetimibearmwas95mg/dl.AlargerpercentageofpatientsintheezetimibearmreachedtargetLDLgoals.Resultsweresimil

6、aracrossthedifferentstatinbrandsandbytheprespecifiedsubgroupsofagegroup,gender,anddiabetesstatus.EzetimibePlaceboReachedTargetLDLGoalsp<0.001mg/dlEzetimibePlaceboReductioninLDLp<0.001PresentedatACCScientificSessions2004EASETrialReachedTargetLDLGoalsp<0.001mg/dlSimilarresultswereobservedint

7、heCHD/CHDriskequivalentsubgroup,themultipleriskfactorsubgroup,andthe<2CHDriskfactorsubgroup.Therewerenoincreasesinthefrequencyofalanineaminotransferase(ALT)≥3timesupperlimitofnormal(ULN)(0.4%forezetimibevs.0.2%forplacebo),aspartateaminotransferase(AST)≥3timesU